Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept.

Authors:
Richard P Baum
Richard P Baum
THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging
Germany
Christiane Schuchardt
Christiane Schuchardt
THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging (PET/CT) ENETS Center of Excellence
Gerd Fabian Volk
Gerd Fabian Volk
Jena University Hospital
Germany
Harshad Kulkarni
Harshad Kulkarni
THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging

Nucl Med Mol Imaging 2018 Feb 11;52(1):80-81. Epub 2018 Jan 11.

1Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany.

The dose-limiting salivary gland toxicity of Ac-labelled PSMA for treatment of metastatic, castration-resistant prostate cancer remains unresolved. Suppressing the metabolism of the gland by intraparenchymal injections of botulinum toxin appears to be a promising method to reduce off-target uptake. A Ga-PSMA PET/CT scan performed 45 days after injection of 80 units of botulinum toxin A into the right parotid gland in a 63-year-old patient showed a decrease in the SUVmean in the right parotid gland of up to 64% as compared with baseline. This approach could be a significant breakthrough for radioprotection of the salivary glands during PSMA radioligand therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13139-017-0508-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777965PMC
February 2018
3 Reads

Publication Analysis

Top Keywords

botulinum toxin
12
gland toxicity
8
psma radioligand
8
radioligand therapy
8
salivary gland
8
parotid gland
8
gland
5
off-target uptake
4
reduce off-target
4
uptake ga-psma
4
method reduce
4
pet/ct scan
4
performed 45 days
4
scan performed
4
promising method
4
ga-psma pet/ct
4
appears promising
4
suppressing metabolism
4
unresolved suppressing
4
remains unresolved
4

Similar Publications

Radiation Dosimetry for Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions.

J Nucl Med 2017 Mar 22;58(3):445-450. Epub 2016 Sep 22.

Department of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is increasingly used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed doses for normal organs and tumor lesions using Lu-PSMA I&T (I&T is imaging and therapy) in patients undergoing up to 4 cycles of radioligand therapy. Results were compared with pretherapeutic Glu-NH-CO-NH-Lys-(Ahx)-[Ga(HBEDCC)] (Ga-PSMA-HBED-CC) PET. Read More

View Article
March 2017

Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.

Eur J Nucl Med Mol Imaging 2015 Dec 31;42(13):1976-83. Epub 2015 Jul 31.

Department of Nuclear Medicine, Yeditepe University Medical Faculty, Istanbul, Turkey.

Purpose: (177)Lu-617-prostate-specific membrane antigen (PSMA) ligand seems to be a promising tracer for radionuclide therapy of progressive prostate cancer. However, there are no published data regarding the radiation dose given to the normal tissues. The aim of the present study was to estimate the pretreatment radiation doses in patients who will undergo radiometabolic therapy using a tracer amount of (177)Lu-labeled PSMA ligand. Read More

View Article
December 2015

Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.

Nucl Med Commun 2017 Jan;38(1):91-98

Departments of aNuclear Medicine bMedical Oncology cUrology, All India Institute of Medical Sciences, New Delhi, India.

Objective: Lu-DKFZ-PSMA-617, a urea-based compound, binds to the extracellular domain of prostate-specific membrane antigen, thus providing an effective target for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Before its therapeutic use, it is necessary that the radiation dosimetry of this radiopharmaceutical be studied to determine the safe activity that can be administered in patients to prevent haematological, renal and liver toxicity. The present study thus aimed to assess the pharmacokinetics and dosimetry of Lu-DKFZ-PSMA-617 in CRPC patients. Read More

View Article
January 2017

Impact of external cooling with icepacks on Ga-PSMA uptake in salivary glands.

EJNMMI Res 2018 Jul 3;8(1):56. Epub 2018 Jul 3.

Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, Netherlands.

Background: External cooling of the salivary glands is advised to prevent xerostomia in lutetium-177-PSMA treatment for advanced prostate cancer. Since evidence addressing this subject is sparse, this study aims to determine impact of icepacks application on uptake in salivary glands. Eighty-nine patients referred for gallium-68-PSMA PET/CT for (re)staging of prostate cancer were prospectively included. Read More

View Article
July 2018